Cite
HARVARD Citation
Voskoboynik, M. et al. (2014). 'Charting a new course for prostate cancer' – currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert review of anticancer therapy. 14 (11), pp. 1253-1256. [Online].